



Express Mail No.: EV 869897377 US
Date of Deposit: July 11, 2008

Page 1 of 1
Attorney Docket No.: 27331-501CIP2A

Modified Form 1449/PTO	Application Number	10/770,639
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Filing Date	February 2, 2004
	First Named Inventor	Sanchez-Madrid
	Group Art Unit	1644
	Examiner Name	Zachary S. Skelding
	Attorney Docket Number	27331-501CIP2A

U.S. PATENT DOCUMENTS								
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date if Appropriate	

U.S. PUBLISHED APPLICATION DOCUMENTS								
Exam Initials	Cite No.	U.S. Published Application No.	Published Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date if Appropriate	

FOREIGN PATENT DOCUMENTS						
Exam Initials	Cite No.	Foreign Patent Document Office	Document Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS						
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.				
	C45	Hamann et al., "AICL: a new activation-induced antigen encoded by the human NK gene complex", <i>Immunogenetics</i> , 45:295-300 (1997)				

* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. _____, filed _____, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ACTIVE 4377800v.1

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /Z.S./



Express Mail No.: EV 869897377 US
Date of Deposit: July 11, 2008

Page 1 of 1
Attorney Docket No.: 27331-501CIP2A

Modified Form 1449/PTO		Application Number	10/770,639
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Filing Date	February 2, 2004
First Named Inventor		Sanchez-Madrid	
Group Art Unit		1644	
Examiner Name		Zachary S. Skelding	
Attorney Docket Number		27331-501CIP2A	

U. S. PATENT DOCUMENTS								
Exam Initials	Cite No.	U. S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate	

U. S. PUBLISHED APPLICATION DOCUMENTS								
Exam Initials	Cite No.	U. S. Published Application No.	Published Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate	

FOREIGN PATENT DOCUMENTS						
Exam Initials	Cite No.	Foreign Patent Document Office	Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS						
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.				
	C45	Hamann et al., "AICL: a new activation-induced antigen encoded by the human NK gene complex", <i>Immunogenetics</i> , 45:295-300 (1997)				

* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. _____, filed _____, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature	/Zachary Skelding/	Date Considered	07/16/2009
--------------------	--------------------	-----------------	------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ACTIVE 4377800v.1

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /Z.S./